Joan Carles Trullàs Vila2024-04-09T10:50:40+02:00

Joan Carles Trullàs Vila

Coordinator of the Clinical research on prevalent community diseases research line in the TR2Lab

ORCID: 0000-0002-7380-3475

Scientific Profile: URECERCA

Dr. Trullàs is an Internal Medicine specialist (2005) who is currently Head of the Internal Medicine Department at Hospital de Olot (Girona). He developed his PhD (doctoral thesis) in Medicine at the Infectious Disease Department, (Hospital Clínic de Barcelona, Universitat de Barcelona) on clinical and epidemiology of kidney disease among patients with HIV infection (2011). He is also Master in AIDS (2005) by Universitat de Barcelona, Master in Cardiovascular Diseases (2012) by Universitat de Barcelona and Postgraduate in Educational Statistisc and Research Methods (2008) by Universitat Autonoma de Barcelona.

Since 2008 he is involved in the “Heart Failure and Atrial Fibrillation working group” of the Spanish Society on Internal Medicine, collaborating and leading clinical research projects on chronic and cardiovascular diseases  (he is the current coordinator of the RICA-2 registry and principal investigator of the CLOROTIC trial -NCT01647932- (clinical registries www.registrorica.com and clinical trials www.clorotic.org). He is very interested and conducting studies on diuretic strategies and mechanisms of diuretic resistance. 

As a professor, for 10 years he has been working as associate lecturer in Medicine at the University of Girona and he is currently lecturer in Medicine at Universitat de Vic-Central de Catalunya and the Director of the Medical Education Cathedra.

My last happenings:

Cardiac resynchronization therapy in acute heart failure and left bundle-branch block in a real-life registry

Authors: Oriol Aguiló, Joan Carles Trullàs, Begoña Espinosa, Pedro López-Ayala, Víctor Gil,10 María Luisa López-Grima, Pablo Herrero-Puente, Javier Jacob, María Pilar López-Díez, José Manuel Garrido, Javier Millán, Alfonso Aguirre, Pascual Piñera, Christian E. Müller, Pere Llorens, Òscar Miro. Abstract Objective: To determine the prevalence, characteristics, timing of implementation and prognosis of patients with left bundle branch block (LBBB) and acute heart failure (AHF) treated with cardiac resynchronization therapy (CRT) in a real-life registry. Methods: We analysed the characteristics of patients with AHF and LBBB at the time of inclusion in the EAHFE (Epidemiology Acute [...]

June 13, 2024|

Prevalence and impact on prognosis of right-bundle branch block in patients with acute heart failure: Findings from the RICA registry

Objectives This work aims to determine the prevalence, characteristics, and impact on prognosis of right bundle branch block (RBBB) in a cohort of acute heart failure (AHF) patients. Methods We prospectively analyzed 3,638 AHF patients included in the RICA registry (National Heart Failure Registry of the Spanish Internal Medicine Society). We independently analyzed the relationship between baseline and clinical characteristics and the presence of RBBB as well as the potential impact of RBBB on 1-year all-cause mortality and a composite endpoint of 90-day post-discharge hospitalization or death. Results The prevalence of RBBB was 10.9%. Patients with RBBB were older, [...]

January 18, 2024|

QT interval and short-term outcome in acute heart failure

Article: QT interval and short-term outcome in acute heart failure Authors: Òscar Miró, Oriol Aguiló, Joan Carles Trullàs, Víctor Gil, Begoña Espinosa, Javier Jacob, Pablo Herrero-Puente, Josep Tost, María Luísa López-Grima, Pere Comas, Carlos Bibiano, Lluís Llauger, Enrique Martin Mojarro, María Pilar López-Díez, Julio Núñez, Zubaid Rafique, Kelly R.Keene, Frank Peacock, Pedro Lopez-Ayala, Christian Mueller, Manuel Montero Pérez-Barquero, Lluís Mont, Pere Llorens on behalf of the ICA-SEMES research investigators. Abstract: Objective To investigate the association of corrected QT (QTc) interval duration and short-term outcomes in patients with acute heart failure (AHF). Methods We analyzed AHF patients [...]

April 10, 2023|
Go to Top